For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.

Pharma News for Sarepta, Astellas, SiSaf, ImmPACT Bio, Otsuka

FDA Approves Rexulti for Agitation Associated With Dementia Due to

Brexpiprazole For Alzheimer's Agitation - Is The Juice Worth The

New approaches to symptomatic treatments for Alzheimer's disease

For Alzheimer's Agitation, Promising News from Rexulti

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Rexulti: Side effects, dosage, alternatives, and more

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

FDA Advisors Endorse Rexulti for Agitation in Alzheimer's Dementia

First Treatment for Agitation Associated With Alzheimer Disease

REXULTI® (brexpiprazole), SZ